JCJosette Carnahan

Josette Carnahan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Josette Carnahan has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Richard Kendall

    Authors' Affiliations: Departments of 1Hematology & Oncology Research, 2Pharmacokinetics & Drug Metabolism, 3Pathology and Comparative Biology Safety Sciences, 4Medicinal Chemistry, and 5Pharmaceutics, Amgen, Inc., Thousand Oaks, California; and 6Department of Molecular Structure, Amgen Inc., Cambridge, Massachusetts

    2 shared publications
  • Adrian L. Smith

    Authors' Affiliations: Departments of 1Hematology & Oncology Research, 2Pharmacokinetics & Drug Metabolism, 3Pathology and Comparative Biology Safety Sciences, 4Medicinal Chemistry, and 5Pharmaceutics, Amgen, Inc., Thousand Oaks, California; and 6Department of Molecular Structure, Amgen Inc., Cambridge, Massachusetts

    1 shared publication
  • Alessandra Cesano

    1 shared publication
  • Brent Kern

    1 shared publication
  • Brian Belmontes

    Authors' Affiliations: Departments of 1Hematology & Oncology Research, 2Pharmacokinetics & Drug Metabolism, 3Pathology and Comparative Biology Safety Sciences, 4Medicinal Chemistry, and 5Pharmaceutics, Amgen, Inc., Thousand Oaks, California; and 6Department of Molecular Structure, Amgen Inc., Cambridge, Massachusetts

    1 shared publication
  • Carol Babij

    Authors' Affiliations: Departments of 1Hematology & Oncology Research, 2Pharmacokinetics & Drug Metabolism, 3Pathology and Comparative Biology Safety Sciences, 4Medicinal Chemistry, and 5Pharmaceutics, Amgen, Inc., Thousand Oaks, California; and 6Department of Molecular Structure, Amgen Inc., Cambridge, Massachusetts

    1 shared publication

Latest Publications

  • Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth

    by Josette Carnahan, Pedro J. Beltran, Carol Babij, Quynh Le, Mark J. Rose, Steven Vonderfecht, Joseph L. Kim, Adrian L. Smith, Karthik Nagapudi, Martin A. Broome, et al.

    Raf inhibitors are under clinical investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf. Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg). However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling. In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo. Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf. Either A-Raf or C-Raf mediated the Raf inhibitor–induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner. These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo. Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested. An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients. Mol Cancer Ther; 9(8); 2399–410. ©2010 AACR.


    • 1 September 2003
      • Vol. 9, 3982S-90S

    Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.

    by Josette Carnahan, Paul Wang, Richard Kendall, Ching Chen, Sylvia Hu, Tom Boone, Todd Juan, Jane Talvenheimo, Silvia Montestruque, Jilin Sun, et al.

    Epratuzumab is a novel humanized antihuman CD22 IgG1 antibody that has recently shown promising clinical activity, both as a single agent and in combination with rituximab, in patients with non-Hodgkin's lymphomas (NHL). In an attempt to better understand the mode of action of epratuzumab, the antibody was tested in vitro in a variety of cell-based assays similar to those used to evaluate the biological activity of other therapeutic monoclonal antibodies, including rituximab. In this report, we present epratuzumab activities as they relate to binding, signaling, and internalization of the receptor CD22. Chinese hamster ovary-expressed CD22 extracellular domain was used to measure epratuzumab affinity on Biacore. CD22 receptor density and internalization rate were measured indirectly using a monovalently labeled, noncompeting (with epratuzumab) anti-CD22 antibody on Burkitt lymphoma cell lines, primary B cells derived from fresh tonsils, and B cells separated from peripheral blood samples obtained from patients with chronic lymphocytic leukemia or healthy volunteers. Epratuzumab-induced CD22 phosphorylation was measured by immunoprecipitation/Western blot and compared with that induced by anti-IgM stimulation. Epratuzumab binds to CD22-extracellular domain, with an affinity of K(D) = 0.7 nM. Binding of epratuzumab to B cell lines, or primary B cells from healthy individuals and patients with NHL, results in rapid internalization of the CD22/antibody complex. Internalization appears to be faster at early time points in cell lines than in primary B cells and NHL patient-derived B cells, but the maximum internalization reached is comparable for all B cell populations after several hours of treatment and appears to reach saturation at antibody concentrations of 1-5 micro g/ml. Finally, epratuzumab binding results in modest but significant CD22 phosphorylation. Epratuzumab represents an excellent anti-CD22 ligating agent, highly efficacious in inducing CD22 internalization, and can induce phosphorylation. Although we cannot unequivocally demonstrate here that epratuzumab-induced internalization and signaling of CD22 directly contribute to its therapeutic efficacy, these properties are the fundamental characteristics of the target CD22 and its interaction with epratuzumab. Similar results were observed when epratuzumab was tested in vitro on Burkitt B cell lines as well as on primary normal B cells and neoplastic B cells separated from fresh peripheral blood samples from patients with chronic lymphocytic leukemia.